Related Experiment Video
Updated: Mar 22, 2026
12:05
Production of Disulfide-stabilized Transmembrane Peptide Complexes for Structural Studies
Published on: March 6, 2013
14.7K
Biotechnology Based Process for Production of a Disulfide-Bridged Peptide
Animesh Goswami, Steven L Goldberg, Ronald L Hanson
1Discovery, R&D, Bristol-Myers Squibb , Route 206 and Province Line Road, Princeton, New Jersey 08543, United States.
Bioconjugate Chemistry
|April 22, 2016
Summary
A novel biotechnology process efficiently produces a disulfide-bridged peptide drug candidate using a leucine zipper system for controlled chain assembly and disulfide bond formation in recombinant E. coli.
Area of Science:
- Biotechnology
- Protein Engineering
- Drug Development
Background:
- Disulfide-bridged peptides are important drug development candidates.
- Efficient and scalable production methods are crucial for these complex molecules.
Purpose of the Study:
- To develop an efficient biotechnology-based process for producing a specific disulfide-bridged peptide drug candidate.
- To engineer a novel heterodimeric system for controlled disulfide bond formation.
Main Methods:
- Designing fusion proteins incorporating leucine zipper components for heterodimerization.
- Expressing fusion proteins in recombinant Escherichia coli (E. coli).
- Utilizing enzymatic/chemical cleavage and specific cleavage (cyanogen bromide) for peptide isolation.
Main Results:
- Successful production of individual oligopeptide chains via recombinant expression.
- Development of a heterodimeric system that facilitates interchain disulfide bond formation.
- Isolation of the target disulfide-bridged peptide through a multi-step purification and cleavage process.
Conclusions:
- The developed process enables efficient production of disulfide-bridged peptides.
- The leucine zipper-based heterodimeric system is effective for controlled disulfide bond formation.
- This approach offers a scalable method for peptide drug candidate manufacturing.
More Related Videos
Related Concept Videos
01:30Production of Pharmaceuticals
22
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
22
01:26Protein Modifications in the RER
7.4K
Modification of secretory and transmembrane proteins entering the rough ER begins in the ER lumen. These modifications aid in protein folding and stabilize the acquired tertiary structure. Protein modifications in the rough ER co-occur at different stages of protein folding.
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal...
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal...
7.4K
02:26Preparation and Reactions of Sulfides
5.9K
Sulfides are the sulfur analog of ethers, just as thiols are the sulfur analog of alcohol. Like ethers, sulfides also consist of two hydrocarbon groups bonded to the central sulfur atom. Depending upon the type of groups present, sulfides can be symmetrical or asymmetrical. Symmetrical sulfides can be prepared via an SN2 reaction between 2 equivalents of an alkyl halide and one equivalent of sodium sulfide.
5.9K
02:33Preparation and Reactions of Thiols
7.9K
Thiols are prepared using the hydrosulfide anion as a nucleophile in a nucleophilic substitution reaction with alkyl halides. For instance, bromobutane reacts with sodium hydrosulfide to give butanethiol.
7.9K